One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday.

But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and Ozlem Tureci (CMO), said they would depart to set up a new biotech firm at the end of 2026.

Still, there’s a very strong case to be made for why this announcement could actually prove positive for the long-term health and trajectory of the BioNTech stock.

How the new biotech startup may help BioNTech stock

BNTX will contribute “related rights and mRNA technologies” to its cofounders’ new company in exchange for a minority stake, milestone payments, and sales royalties.

What this means is: BioNTech is essentially “outsourcing” the most expensive and speculative part of biotechnology – early-stage research and development (R&D).

The benefit: BioNTech stops burning its cash on moonshot mRNA ideas that might take a decade to pay off.

The upside: By retaining a minority stake and securing milestone/royalty rights, BioNTech keeps a “call option” on whatever the founders discover next.

If they find the “next big thing,” BNTX stock gets a cut without having carried the full overhead costs.

Simply put, as founders focus on the “R” (Research), BioNTech will get to focus entirely on “D” (Development), taking a proven candidate through a brutal regulatory and commercialization gauntlet to become a “multi-product company” by the end of this decade.

Why leadership change may prove positive for BNTX shares

What’s also worth mentioning is that founders like Ugur Sahin and Ozlem Tureci are often wartime or discovery leaders.

They thrive on the bench, not in boardrooms managing thousands of employees and earnings calls.

Therefore, by bringing in professional executive leadership, BNTX may transition into a structured, execution-focused machine.

Meanwhile, instead of its founders feeling trapped by corporate duties, they stay aligned with the biotech firm through the equity stake, potentially acting as a high-powered external R&D lab.

This could also help unlock further upside in BioNTech shares over time.

How to play BioNTech after disappointing Q4 earnings print

Despite the headlines, BioNTech’s financial foundation remains one of the strongest in the biotech sector.

The company ended 2025 with a staggering €17.2 billion in cash and securities – providing a huge “war chest” to fund its transition without needing to tap the capital markets.

Furthermore, while COVID-19 revenues are normalizing, 2025 revenues of €2.9 billion actually exceeded the firm’s own increased guidance.

The “bull case” for BNTX shares now shifts to a clinical calendar packed with value-inflection points.

BioNTech is entering its most active phase yet, with 15 Phase 3 trials expected to be ongoing by the end of 2026 and seven late-stage data readouts scheduled for this year alone.

By offloading early-stage R&D risks to the founders’ new venture, BioNTech can laser-focus its capital on these high-potential assets like its PD-L1/VEGF bispecific backbone and its promising ADC portfolio to meet its goal of becoming a multi-product oncology powerhouse by 2030.